N4 101 In Vivo Study Results

Thalia Therapeutics

12/05/2025 07:00

RNS Number : 1308I

N4 Pharma PLC

12 May 2025

 

 

12 May 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

N4 101 In Vivo Study Results

 

Positive results from first in vivo study of dual-loaded Nuvec® for IBD

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce positive results from its first in vivo study evaluating the use of its Nuvec® proof-of-concept programme, N4 101, an orally delivered anti-inflammatory treatment for Inflammatory Bowel Disease (IBD).

 

Following the successful completion of in vitro profiling in December 2024, N4 Pharma has now completed its first in vivo study using an industry-standard mouse model of IBD. The study explored the therapeutic potential of orally administered Nuvec® particles loaded with siRNA alone and combined with mRNA.

 

Over a nine-day dosing period, mice with chemically induced acute IBD received single (siRNA) or dual (siRNA and mRNA) Nuvec®-loaded formulations, and versions of these therapies specifically targeted at cells involved in gut inflammation using modified Nuvec® particles. Samples were collected for analysis on day 15.

 

Key highlights from the study include:

 

•
Reduction in inflammation:both single anddual-loadedNuvec® particles demonstrated marked improvements compared with controls across all key indicators of colitis, including Disease Activity Index (DAI), colon length, and body weight loss.
•
Marked increase in efficacy achieved with targeting:both the single and dual loaded Nuvec® combined with a targeting agent performed better and showed an even greater reduction in the inflammatory marker TNF alpha than the untargeted therapies.
•
Sustained therapeutic effect:six days after the final administration, both single and dual-loaded targeted Nuvec® particles showed a near complete reduction in TNF alpha levels in intestinal tissues.
•
Effective oral delivery:the study also provides clear in vivo evidence that Nuvec® particles successfully deliver therapeutic nucleic acid cargos (siRNA and mRNA) to the gut via oral administration, resulting in the sustained anti-inflammatory effects observed.

 

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

"We are delighted with these very promising in vivo data, which demonstrate a sustained anti-inflammatory effect in a validated IBD model - a major milestone for our N4 101 programme. Demonstrating a clear increase in performance through targeting the treatment to specific cells is the holy grail of nucleic acid therapeutics, and these results place Nuvec® at the leading edge of nucleic acid delivery technologies. 

"The study also provides good evidence that Nuvec® can successfully deliver nucleic acid therapies to the gut via oral administration, opening up exciting new possibilities for orally delivered therapies for gastrointestinal diseases such as IBD and some cancers.

"This work is at an early stage, but as we move into optimisation studies, these findings will continue to add to our data set along with the extensive studies supported by the recent fundraise, to validate Nuvec® as a novel delivery platform for advanced therapies, strengthening our discussions with commercial partners.

"We look forward to advancing this programme into the next phase of development and providing further updates on this and our broader platform work plans for the coming months in due course."

-      Ends -

 

For more information, please contact:

 

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:investors.n4pharma.com
https://investors.n4pharma.com/link/8r6zor
SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
RESUKSORVOUVRAR